The Science of


The Science

Alzheimer’s disease, one of the most significant global health threats we face today, is an ailment that, as our population ages, could quickly grow to become a worldwide epidemic. However, we now understand that Alzheimer’s disease is not a genetic destiny. With the ReCODE protocol, a partnership between AHNP Precision Health and vanguard Alzheimer’s researcher Dr. Dale Bredesen, patients exhibiting early signs of cognitive decline are finally able to take their brain health back into their own hands. Real reversal of this debilitating condition is possible.

The ReCODE protocol is based on scientific research that has led to new insights uncovering the physical mechanism behind the erosion of memory seen in Alzheimer’s disease, and this means we now know why and where Alzheimer’s disease happens. This has opened the door to new approaches to treating Alzheimer’s disease. These are treatments that challenge the idea that memory loss, cognitive decline, and Alzheimer’s disease are foregone conclusions. In fact, science is telling us, these mental health ailments are not just treatable, but preventable in the first place.

We want to share with you the science that both underlies the ReCODE protocol, and proves that Alzheimer’s disease can not just be prevented, but that Alzheimer’s disease can be treated and, in some cases, reversed. Dr. Bredesen has spearheaded this research, and many of his abstracts and studies can be found below.

The Protocol

The Protocol provides a comprehensive personalized program designed to improve cognition and reverse the cognitive decline of SCI, MCI, and early Alzheimer's disease. Continued research and testing by Dr. Bredesen began by evolving MEND into the ReCODE Protocol, which has identified new and previously unrecognized causes of Alzheimer's disease.

ReCODE is designed to be the optimal starting point and road map for you and your trained practitioner to reverse your symptoms, with the help of personalized genetic information, hormonal support, nutritional advice, and Dr. Bredesen’s cutting-edge research.

The Bredesen Protocol:

Ready to take the first step towards taking control of your brain's destiny? Dr. Bredesen’s research has fundamentally altered everything we thought we knew about Alzheimer’s disease. Take a look at the science underlying the groundbreaking Bredesen and ReCODE Protocol.

Reversal of Cognitive Decline:

Dr. Bredesen presents his work on how nutritional intervention and reducing environmental risk factors can best be implemented as part of an individualized treatment plan for reversing depression and Alzheimer’s.

Reversal of Cognitive Decline:

Dr. Bredesen presents his work on how nutritional intervention and reducing environmental risk factors can best be implemented as part of an individualized treatment plan for reversing depression and Alzheimer’s.

Reversing Alzheimer's:

In this wide-ranging discussion with Dr. Mark Hyman, Dr. Bredesen discusses his “radical approach to rethinking Alzheimer’s.”


Keep up to date with Dr. Bredesen's latest research!

Reversal of Cognitive Decline: 100 Patients
The first examples of reversal of cognitive decline in Alzheimer’s disease and the pre-Alzheimer’s disease conditions MCI (Mild Cognitive Impairment) and SCI (Subjective Cognitive Impairment) have recently been published. These two publications described a total of 19 patients showing sustained subjective and objective improvement in cognition, using a comprehensive, precision medicine approach that involves determining the potential contributors to the cognitive decline (e.g., activation of the innate immune system by pathogens or intestinal permeability, reduction in trophic or hormonal support, specific toxin exposure, or other contributors), using a computer-based algorithm to determine subtype and then addressing each contributor using a personalized, targeted, multi-factorial approach dubbed ReCODE for reversal of cognitive decline.

An obvious criticism of the initial studies is the small number of patients reported. Therefore, we report here 100 patients, treated by several different physicians, with documented improvement in cognition, in some cases with documentation of improvement in electrophysiology or imaging, as well. This additional report provides further support for a randomized, controlled clinical trial of the protocol and the overall approach.

Reversal of Cognitive Decline in Alzheimer’s Disease
Alzheimer’s disease is one of the most significant healthcare problems nationally and globally. Recently, the first description of the reversal of cognitive decline in patients with early Alzheimer’s disease or its precursors, MCI (mild cognitive impairment) and SCI (subjective cognitive impairment), was published.  The therapeutic approach used was programmatic and personalized rather than monotherapeutic and invariant, and was dubbed metabolic enhancement for neurodegeneration (MEND). Patients who had to discontinue work were able to return to work, and those struggling at work were able to improve their performance. The patients, their spouses, and their co‐workers all reported clear improvements. READ THE STUDY

Transcriptional Effects of ApoE4: Relevance to Alzheimer's Disease
The major genetic risk factor for sporadic Alzheimer's disease (AD) is the lipid binding and transporting carrier protein apolipoprotein E, epsilon 4 allele (ApoE4). One of the unsolved mysteries of AD is how the presence of ApoE4 elicits this age-associated, currently incurable neurodegenerative disease. Recently, we showed that ApoE4 acts as a transcription factor and binds to the promoters of genes involved in a range of processes linked to aging and AD disease pathogenesis. READ THE STUDY

Downregulation of protein phosphatase 2A by apolipoprotein E: Implications for Alzheimer's disease.
The apolipoprotein E ε4 allele is the single most important genetic risk factor associated with Alzheimer's disease (AD). Tau phosphorylation and hyperphosphorylation is an underlying feature of AD and is regulated by specific kinases and phosphatases. Among phosphatases, protein phosphatase 2A (PP2A) is the principal tau dephosphorylating enzyme in the brain. Several abnormalities of PP2A have been reported in AD, including among others decreased protein levels of PP2A, decreased mRNA and protein levels of the catalytic subunit PP2AC and variable regulatory B subunits and reduced methylation of the catalytic subunit, all of which results in disruption of the PP2A phosphatase activity. READ THE STUDY


Get In Touch

We would love to hear from you. Contact us by clicking the Help button with any questions or call us at 1.800.450.0805.

Due to increased interest in the ReCODE Report and ReVERSE Program, you may experience a delay in response time.

Terms of Service | Privacy Statement